Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WM-S1-030 in Advanced Solid Tumors
NCT04801095Phase 1Unknown
- Sponsor
- Wellmarker Bio
- Start
- Jul 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of wm-s1-030 in solid tumor (advanced stage), metastatic solid tumor, colorectal cancer (CRC) and 4 more, sponsored by Wellmarker Bio. Primary endpoints: Incidence of Dose-limiting toxicities and Incidence of adverse events and serious adverse events. Status: unknown.
02
Drugs
wm-s1-030
03
Conditions
solid tumor (advanced stage)metastatic solid tumorcolorectal cancer (CRC)lung cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04801095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801095.